Poster: Epigenetic Target BRD3 – Fragment-based Hit Discovery
Sygnature Discovery has successfully created a unique fragment library, characterized by its high level of novelty and extensive coverage of chemical diversity. This proprietary library comprises more than 900 compounds, a significant portion of which are not commercially accessible. The library’s design was guided by the ‘rule of 3’ and focused on achieving a broad range of structural diversity.
To showcase the potential of this fragment-based drug discovery approach, Sygnature Discovery conducted a screening experiment using the library. The target selected for this study is the epigenetic protein Bromodomain-containing protein 3 (BRD3 or RING3L), an area of drug discovery with limited existing literature. The screening aimed to demonstrate the effectiveness of the library in identifying promising fragments for further drug development.